CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

被引：0
|
作者：
Xinna Zhou
Guoliang Qiao
Xiaoli Wang
Qingkun Song
Michael A. Morse
Amy Hobeika
William R. Gwin
Jun Ren
H. Kim Lyerly
机构：
[1] Capital Medical University Cancer Center,Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines
[2] Beijing Shijitan Hospital,Department of Medical Oncology
[3] Capital Medical University,Department of Medicine
[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Department of Surgery
[5] Beijing Cancer Hospital and Institute,Department of Medicine
[6] Peking University School of Oncology,undefined
[7] Duke University Medical Center,undefined
[8] Duke University Medical Center,undefined
[9] University of Washington,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
CYP1A1; Single nucleotide polymorphism; Breast cancer; Liver metastasis; Docetaxel; Thiotepa; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 372
页数：7
相关论文
共 50 条
  • [11] Optimize Administration Protocol of Capecitabine Plus Docetaxel Combination in Metastatic Breast Cancer Patients
    Frances, Nicolas
    Woloch, Christian
    Marouani, Hafedh
    Mercier, Cedric
    Iliadis, Athanassios
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (15) : 1665 - 1668
  • [12] Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer
    Wenzel, C
    Bartsch, R
    Locker, GJ
    Hussian, D
    Pluschnig, U
    Sevelda, U
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    Steger, GG
    ANTI-CANCER DRUGS, 2005, 16 (04) : 441 - 445
  • [13] First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
    Liang, Xu
    Yan, Ying
    Wang, Lina
    Song, Guohong
    Di, Lijun
    Jiang, Hanfang
    Wang, Chaoying
    Li, Huiping
    ONCOLOGY LETTERS, 2015, 9 (02) : 987 - 993
  • [14] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [15] Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European Phase III trial
    Chan, S
    EJC SUPPLEMENTS, 2005, 3 (05): : 17 - 21
  • [16] A phase III trial of Gemcitabine plus Docetaxel (GD) versus Capecitabine plus Docetaxel (CD) for patients (pt) with anthracycline-pretreated metastatic breast cancer
    Chan, S.
    Sharma, R.
    Romieu, G.
    Huober, T.
    Delozier, T.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, A.
    Fumoleau, P.
    EJC SUPPLEMENTS, 2007, 5 (03): : 15 - 16
  • [17] BUDGET IMPACT ANALYSIS OF EVEROLIMUS PLUS EXEMESTANE VERSUS GEMCITABINE PLUS PACLITAXEL AND CAPECITABINE PLUS DOCETAXEL IN METASTATIC BREAST CANCER PATIENTS IN EGYPT
    Elsisi, G.
    Saeed, E.
    Elmahdawy, M.
    VALUE IN HEALTH, 2014, 17 (07) : A622 - A622
  • [18] Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines
    Martí, JL
    Bueso, P
    Mayordomo, JI
    Isla, MD
    Saenz, A
    Escudero, P
    Murillo, L
    Filipovich, E
    Andres, R
    Tres, A
    ANNALS OF ONCOLOGY, 2001, 12 (08) : 1061 - 1065
  • [19] Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer
    Bian, Li
    Wang, Tao
    Zhang, Shaohua
    Jiang, Zefei
    TUMOR BIOLOGY, 2013, 34 (05) : 3153 - 3158
  • [20] Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study
    Abudureheiyimu, Nilupai
    Wu, Yun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Han, Yiqun
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 115 - 120
12345